Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Related PFE
Pharma ETFs in Focus on String of Earnings Beat - ETF News And Commentary
Stocks Mixed Despite Better Than Expected GDP
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters